MICHELE NOVELLA: Open Payments
NPI 1750307948 · DANBURY, CT. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$134,139 in 318 payments from 19 companies in 2025. Trend: 2023 $38,079 · 2024 $135,629 · 2025 $134,139
Honoraria: $61,900Travel & lodging: $28,845Speaker / faculty: $22,485Consulting: $8,880Food & beverage: $6,721Speaker / faculty: $5,309
| Company | Payments | Amount |
|---|---|---|
| Axsome Therapeutics, Inc. | 123 | $85,317 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 55 | $29,757 |
| Alkermes, Inc. | 12 | $6,333 |
| E.R. Squibb & Sons, L.L.C. | 10 | $5,517 |
| Vertical Pharmaceuticals, LLC | 3 | $5,330 |
| ABBVIE INC. | 41 | $552 |
| Corium, LLC | 17 | $253 |
| Takeda Pharmaceuticals U.S.A., Inc. | 11 | $233 |
| Vanda Pharmaceuticals Inc. | 12 | $233 |
| Otsuka America Pharmaceutical, Inc. | 19 | $181 |
Products named: Auvelity, CAPLYTA, Relexxii, LYBALVI, COBENFY, ARISTADA, VRAYLAR, Azstarys.
Industry payments across CT — which companies pay providers there.
